Is CJC-1295 / Ipamorelin legal in Australia?

The most stacked pair in the peptide market, sold as 5 mg plus 5 mg or 10 mg plus 10 mg in one vial, so each peptide is half the powder by mass. No published study has tested CJC-1295 with ipamorelin in humans or in animals, and the two components have half-lives that differ by roughly a hundredfold, which means no single injection schedule is correct for both.

CJC-1295 and ipamorelin are sold together more often than either is sold alone. The logic vendors give is real pharmacology: CJC-1295 is a growth hormone releasing hormone analogue acting at the GHRH receptor, ipamorelin is a ghrelin mimetic acting at the growth hormone secretagogue receptor, and the two receptors sit on the same pituitary somatotroph.

Mechanism: Two receptors on the same pituitary cell. CJC-1295 activates the GHRH receptor, raising the amplitude of growth hormone pulses; albumin binding through the Drug Affinity Complex extends that signal for days in the DAC version.

Regulatory history: Not approved. Neither component is an approved drug, and the combination has never been submitted or studied.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for CJC-1295 / Ipamorelin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.